Intralesionally implanted cisplatin cures primary brain tumor in rats

Journal of Surgical Oncology

Volumn 64, Issue 4, 1997, Pages 268-275

  Kong, Qingzhong ^a   Kleinschmidt Demasters, Bette K ^a   Lillehei, Kevin O ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

9L gliosarcoma; biodegradable polymer; brain neoplasm; cisplatin; sustained release

Indexed keywords

CISPLATIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GLIOSARCOMA; INTRATUMORAL DRUG ADMINISTRATION; MALE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; RAT; SURVIVAL TIME; SUSTAINED RELEASE PREPARATION;

EID: 0030969672     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199704)64:4<268::AID-JSO4>3.0.CO;2-7     Document Type: Article

References (37)

1. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-911.
2. Tomita T: Interstitial chemotherapy for brain tumors: review. J Neurooncol 1991;10:57-74.
3. Zeller WJ, Bauer S, Remmele T, et al.: Interstitial chemotherapy of experimental gliomas. Cancer Treat Rev 1990;17:183-189.
4. Tamargo RJ, Myseros JS, Epstein JI, et al.: Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 1993;53:329-333.
5. Kimler BF, Liu C, Evans RG, Morantz RA: Intracerebral chemotherapy in the 9L rat brain tumor model. J Neurooncol 1992;14: 191-200.
6. Brem H, Domb A, Lenartz D, et al.: Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid dimer and sebacic acid. J Controlled Release 1992;19:325-330.
7. Walter KA, Cahan MA, Gur A, et al.: Interstitial Taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994;54:2207-2212.
8. Judy KD, Olivi A, Buahin KG, et al.: Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg 1995;82:481-486.
9. Brem H, Mahaley MS Jr, Vick NA, et al.: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441-446.
10. Brem H, Piantadosi S, Berger PC, et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995;345:1008-1012.
11. Thompson SW, Davis LE, Kornfeld M, et al.: Cisplatin neuropathy, clinical, electrophysiology, morphologic, and toxicologic studies. Cancer 1984;54:1269-1275.
12. Donelli MG, Zucchetti M, D'Incalci M: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992;30:251-260.
13. Stewart DJ, Leavens M, Maor M, et al.: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982;42: 2474-2479.
14. Zwelling LA, Kohn KW: Mechanism of action of cis-dichlorodiammine platinum. Cancer Treat 1979;63:1439-1444.
15. 2(d(pGpG)]. Science 1985;230:412-417.
16. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-2362.
17. Kong Q, Lillehei KO, Mitchell DH, et al.: Local sustained release of cisplatin from biodegradable polymer can cure 9L gliosarcoma in the rat [abstract]. Proc Am Assoc Cancer Res 1993;34:365.
18. Lillehei KO, Kong Q, DeMasters BK, Withrow SJ: Local sustained release of cisplatin from biodegradable polymer for the treatment of intracranial glioma in the rat [abstract]. J Neurooncol 1993;15 Suppl:S16.
19. Straw RC, Withrow SJ, Douple EB, et al.: Effects of cis-diamminedichloroplatinum II released from D,L-polylactic acid implanted adjacent to cortical allografts in dogs. J Orthop Res 1994;12:871-877.
20. Skullerud K: Variations in the size of the human brain: influence of age, sex, body length, body mass index, alcoholism, Alzheimer changes and cerebral atherosclerosis. Acta Neurol Scand (Supp) 1985;102:1-94.
21. Bobo H, Kapp JP, Vance RB: Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea(BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: Proposal of a new method of intra-arterial dosage calculation. J Neurooncol 1992;13:291-299.
22. Vance RB, Kapp JP: Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma. J Neurooncol 1986;3:287-290.
23. Neuwelt EA, Howieson J, Frenkel EP, et al.: Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood brain barrier modification in glioblastoma. Neurosurgery 1986;19:573-582.
24. Gumerlock MK, Belshe BD, Madsen R, Watts C: Osmotic blood-brain disruption and chemotherapy in the treatment of high grade malignant glioma: Patient series and literature review. J Neurooncol 1992;12:33-46.
25. Tomiwa K, Hazama F, Mikawa H: Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier. Neuropatho Appl Neurobiol 1983;9:345-354.
26. Nakagawa H, Groothuis D, Blasberg RG: The effect of graded Hypertonic intracarotid infusion on drug delivery to experimental RG-2 gliomas. Neurology 1984;34:1571-1581.
27. Black KL, King WA, Ikezaki K: Selective opening of the blood-tumor barrier by intra-carotid infusion of leukotriene C4. J Neurosurg 1990;72:912-916.
28. Poplack DG, Bleyer WA, Horowitz ME: Pharmacology of antineoplastic agents in cerebrospinal fluid. In Wood JH (eds): "Neurobiology of Cerebrospinal Fluid." New York: Plenum Press, 1980, p 561-578.
29. Deurloo MJ, Kop W, van Tellingen O, et al.: Intratumoral administration of cisplatin in slow-release devices: II. Pharmacokinetics and intratumoral distribution. Cancer Chemother Pharmocol 1991; 27:347-353.
30. Begg AC, Bartelink H, Stewart FA, et al.: Improvement of differential toxicity between tumor and normal tissues using intratumoral injection with or without a slow-drug-release matrix system. NCI Monogr 1988;6:133-136.
31. Nagase M, Nomura T, Nakajima T: Effects of intralesional versus ip administration of cisplatin on squamous cell carcinoma of mice. Cancer Treat Rep 1987;71:825-829.
32. Hecquet B, Chabot F, Delatorre Gonzalez JC, et al.: In vivo sustained release of cisplatin from bioresorbable implants in mice. Anticancer Res 1986;6:1251-1255.
33. Krag DN, Theon AP, Schneider PD, Goodnight JE: Intralesional cis-diamminedichloroplatinum and purified collagen treatment of human metastatic malignancies: A feasibility study. J Surg Oncol 1990;43:83-87.
34. Theon AP, Pascoe JR, Carlson GP, Krag DN: Intratumoral chemotherapy with cisplatin in oily emulsion in horses. J Am Vet Med Assoc 1993;202:261-267.
35. Kroin JS, Penn RD: Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 1982;10:349-354.
36. Kong Q, Lillehei KO, Withrow SJ, DeMasters BK: The effect of local ATP administration as adjuvant therapy for 9L gliosarcoma in rats treated with interstitial sustained release cisplatin [abstract]. Proc Am Assoc Cancer Res 1994;35:331.
37. Lillehei KO, Kong Q, Withrow SJ, DeMasters BK: Cisplatin administered via sustained release biodegradable polymer appears superior to conventionally administered chemotherapy in the treatment of 9L gliosarcoma in rats [abstract]. Proc Am Assoc Cancer Res 1994;35:417.